Former FDA Commissioner Becomes TSRI's Newest Board Member
By Mika Ono
At a recent meeting of The Scripps Research Institute (TSRI)
Board of Trustees, Jane E. Henney, a prominent leader in the
health sciences, was appointed as the newest member of the
"We're very proud to welcome Jane Henney to our Board of
Trustees," says TSRI President Richard Lerner. "As a talented
administrator and former commissioner of the FDA [U.S. Food
and Drug Administration], she brings to the Board a unique
set of insights, experience, and skills."
Henney is currently senior scholar at the Association of
Academic Health Centers, a national, non-profit organization
dedicated to improving health by advancing the leadership
of academic health centers.
From 1998 to early this year, Henney was commissioner of
the FDA, whose mission is to assure the safety of foods and
cosmetics and the safety and efficacy of pharmaceuticals,
biological products, and medical devices within the United
States. The agency has more than 9,200 employees and a budget
of over $1 billion.
Other positions Henney has held include: vice president for
health sciences at the University of New Mexico, deputy commissioner
for operations at the FDA, vice chancellor for health programs
and policy at Kansas University, interim dean of the University
of Kansas School of Medicine, acting director for the University
of Kansas Mid-America Cancer Center, and deputy director of
the National Cancer Institute.
Henney is an elected member of the Institute of Medicine
of the National Academy of Sciences, an honorary fellow of
the American College of Health Care Executives, and an elected
member of the Society of Medical Administrators, among numerous
other awards and honors. She is an active member of several
professional societies and serves on boards in both the not-for-profit
and for-profit sectors.
A graduate of Manchester College and Indiana University School
of Medicine, Henney has authored or co-authored more than
40 scientific papers and book chapters. Much of her research
has focused on advancing therapies for cancers of the breast.
As commissioner of the FDA, Jane Henney
was responsible for managing 9,200 employees and a budget
of over $1 billion.